Alexandria Real Estate Equities, Inc. (ARE) Business Profile

What it does

Alexandria Real Estate Equities is a real estate investment trust, or REIT, that owns, operates, develops and redevelops laboratory-focused properties for life-science and related tenants. Founded in 1994, it is headquartered in Pasadena, and Peter M. Moglia is its chief executive.

Its main product is leased space within “Megacampus” ecosystems: clusters of Class A/A+ laboratory properties near academic and medical research institutions, with amenities, services and transit access. The company builds new generic laboratory facilities and converts acquired office, warehouse or shell space into reusable laboratory space. It generally seeks significant pre-leasing before starting aboveground construction, except where it sees solid demand.

At December 31, 2025, Alexandria had 340 North American properties comprising approximately 39.4 million RSF of operating properties and development and redevelopment properties under construction. Operating-property occupancy was 90.9%. The company also makes selected non-real-estate investments in public and private life-science businesses through its venture-capital platform, subject to REIT restrictions.

Management said on the Q2 2026 call that it had also leased a building at its Andover Megacampus to an advanced-technology tenant rather than completing the originally intended laboratory or biomanufacturing redevelopment.

How it makes money

Alexandria earns recurring rental revenue by leasing laboratory, office and related space to tenants. Lease income depends on occupied square footage, rental rates, contractual annual rent escalations, lease renewals and the timing of new leases commencing. Its development and redevelopment activity is intended to add rentable space and, once delivered and leased, increase rental income, property net operating income and cash flow.

The company operates through geographic markets rather than separately described business-product segments: Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, New York City and Texas. It also earns gains from sales of real estate, land and partial interests, and can realize gains from its life-science venture investments. These are capital-recycling and investment activities rather than the core recurring-rent stream.

For the latest full year, total revenues were $3.03 billion for the year ended December 31, 2025; for Q2 2026, FFO per share diluted as adjusted was $1.73.

Lease structure supports recurring income: 97% of leases had average rent steps approaching 3% at Q2 2026, and remaining lease terms averaged 7.7 years. Management said on the Q2 2026 call that 1.4 million square feet was leased but vacant and expected to commence in November 2026 on average, with expected annual rental revenue of $69 million. The company declared a common-stock dividend of $0.72 per share for the three months ended December 31, 2025, after reducing the prior quarterly dividend to preserve liquidity for its capital plan.

Customers and how it sells

Alexandria serves multinational pharmaceutical companies; public and private biotechnology companies; life-science product, service and medical-device companies; digital-health, advanced-technology and agtech companies; academic and medical research institutions; U.S. government research agencies; non-profit organizations; and venture-capital firms. Its customers rent space directly, rather than through a consumer or distributor channel.

Investment-grade or publicly traded large-cap tenants represented 53% of annual rental revenue in effect at December 31, 2025. Management said on the Q2 2026 call that the share was 57% of annual rental revenue, while public biotech represented 21% of annual rents. Management also said that public-biotech leasing rose to 5.8% of Q2 2026 leasing volume from zero in the preceding quarter.

The portfolio is concentrated in North American life-science innovation clusters: Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, New York City and Texas. Its largest three markets are Greater Boston, San Francisco Bay Area and San Diego. Management said on the Q2 2026 call that its occupancy outperformed the broader markets by approximately 8% to 12% across those three markets at the end of Q2.

Suppliers and costs

The company’s operating costs include property operating expenses, tenant improvements, construction and redevelopment spending, interest expense, payroll and general and administrative expenses. It seeks lease provisions that pass through operating expenses and certain capital expenditures to tenants, while also seeking to minimize tenant-improvement costs.

Development requires entitlements, permitting, design, site work and construction before a building can be delivered. The company relies on a limited number of vendors for utilities and other property services; disruption to those services may affect operations and financial condition. It also uses debt, property dispositions, sales of partial interests, joint-venture capital, equity and investment sales as capital sources.

Management said on the Q2 2026 call that general and administrative expense guidance for 2026 was $134 million to $154 million. It also said capitalized interest was $73.7 million in Q2 2026, affected by the weighted-average interest rate on debt. The company extended its $5 billion unsecured senior line of credit to 2032.

Competitive position

Alexandria competes for tenants with nearby laboratory and technology properties. Available rentable space in a market can affect both its ability to lease space and the rental rates it obtains. It also competes for properties, land and investment opportunities with other REITs, insurance companies, pension and investment funds, private-equity entities, partnerships, developers, investment companies, owners/occupants and foreign investors. Some competing capital providers can deploy more capital, accept more risk, or offer lower rents, more free rent or higher tenant-improvement allowances.

No individually named competing company is supported by the available company information. Management said on the Q2 2026 call that Alexandria accounted for two times its market share of leasing activity in the San Francisco Bay Area and 1.7 times its market share in San Diego during the quarter.

Our reading: The location-based Megacampus model is a meaningful moat because the portfolio clusters space near research institutions and offers tenants room to expand, but it remains exposed to competing space in the same markets. [item1; item7]

Our reading: Long-standing real-estate and life-science relationships and an existing-tenant leasing base support tenant retention, although they do not prevent competitors from using pricing concessions. [item1; item7]

Our reading: The company’s concentration in specialized laboratory space differentiates its assets, but new laboratory supply in the three largest markets weakens the practical protection from that specialization. [item1; item7]

Growth opportunities

Alexandria’s growth plan centers on leasing vacant space, renewing tenants, selectively acquiring properties and land in target clusters, and developing or redeveloping laboratory properties. Its campuses are designed to give tenants a path to expand within the same ecosystem. The company also seeks to convert suitable acquired office, warehouse and shell space into laboratory space that can command higher rental rates.

Management said on the Q2 2026 call that 1.4 million square feet of development and redevelopment projects under construction were expected to stabilize through 2028 and were 71% leased. It also said the pipeline had shrunk by 20% from the beginning of 2026 as it completed projects or considered advanced-technology strategies. The company was evaluating business and financial strategies for 1.4 million square feet across five projects.

Management said on the Q2 2026 call that it executed letters of intent for approximately 109,000 square feet at 311 Arsenal Street, bringing the project’s lease-negotiating percentage to 44%. It expects its disposition, partial-interest sale and other-capital program to fund capital uses; its 2026 guidance midpoint for these sources was $2.9 billion. The company also expects to focus 2027 construction spending on costs required to lease operating properties.

Structural risks

• Life-science demand and funding: Alexandria depends on the health of the life-science industry. Its tenants’ ability to fund research, development and operations can affect rental payments, while conditions can also affect the value of its venture investments.

• Supply, demand and occupancy: New laboratory supply and reduced demand can pressure rental rates, occupancy and operating results. Availability in its three largest markets rose to approximately 29% in 2025 from approximately 4% in 2021, while tenant requirements declined by more than 60% versus 2021.

• Development and lease-up: Acquisitions, developments and redevelopments may not be completed or operated successfully and profitably. Projects require capital and can face lease-up risk, including timing between leasing, construction completion and tenant occupancy.

• Capital and leverage: Adverse credit ratings, refinancing constraints, inability to issue debt, or an inability to sell real-estate and non-real-estate assets at timely or optimal prices could constrain capital. Management said on the Q2 2026 call that later timing of dispositions and partial-interest sales was expected to increase interest expense.

• Tenant expirations and credit: Management said on the Q2 2026 call that 1.4 million square feet of 2027 key lease expirations, with $100.5 million of expiring rent, were expected to have average downtime of 12 to 24 months.

• Property and regulatory liabilities: Environmental contamination, hazardous materials handled by tenants, insurance gaps, climate-related conditions and compliance obligations can create costs, third-party liability or constraints on selling, leasing, developing or financing properties.

Bottom line

Our reading

Our reading: Alexandria is a specialized U.S. life-science property landlord whose recurring economics rest on leasing laboratory campuses, occupancy, tenant credit and rent escalations. [item1; call_prepared]

Our reading: Its principal current exposure is the combination of excess laboratory supply, slower life-science demand and upcoming vacancy, while its capital-recycling program and project reviews are intended to reduce funding needs. [item7; item1a; call_prepared]

Our reading: The portfolio’s cluster locations, long lease terms and large-cap tenant revenue provide support, but their effect depends on converting leased space into occupied space and managing expirations. [item1; call_prepared]